<DOC>
	<DOCNO>NCT02762370</DOCNO>
	<brief_summary>This study double-blind , randomize , parallel group comparison effect FX006 Triamcinolone Acetonide Injectable Suspension , USP ( refer TCA IR protocol ) blood glucose patient osteoarthritis knee Type 2 diabetes mellitus .</brief_summary>
	<brief_title>Study Assess Effects FX006 Blood Glucose Patients With OA Knee Type 2 Diabetes</brief_title>
	<detailed_description>This study double-blind , randomize , parallel group , single-dose study design . The study conduct male female patient ≥ 40 year age osteoarthritis knee Type 2 diabetes mellitus . Approximately 36 patient randomized one two treatment group ( 1:1 ) treat single intra-articular ( IA ) injection : - 40 mg FX006 - 40 mg TCA IR Blood glucose level evaluate total 3 week ( one week prior injection two week post IA injection ) use continuous glucose monitoring device . Following randomization IA injection , patient return follow visit Day 8 , Day 15 Week 6/Day 43 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<criteria>Willingness ability comply study procedure visit schedule ability follow verbal write instruction Male female ≥40 year age Type 2 diabetes mellitus least 1 year prior Screening manage injectable agent ( e.g . insulin insulin analog , exenatide , pramlintide , liraglutid ) Currently treat 1 2 oral agent diabetes , stable dos least 2 month HbA1c ≥6.5 % ≤ 9.0 % Currently meet ACR Criteria ( clinical radiological ) OA . Symptoms associate OA knee ≥ 6 month prior Screening Index knee pain day ( &gt; 15 ) last month ( report patient ) Body mass index ( BMI ) ≤ 40 kg/m2 Willingness abstain use protocolspecified restricted medication study Willingness wear CGM device uninterrupted 24 hour per day throughout study , remain receive range comply calibration requirement Accustomed use Standard Blood Glucose Measuring device finger stick Reiter 's syndrome , rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis arthritis associate inflammatory bowel disease History infection index knee joint Clinical sign symptom active knee infection crystal disease index knee within 1 month Screening Presence surgical hardware foreign body index knee Unstable joint ( torn anterior cruciate ligament ) within 12 month screen IA corticosteroid ( investigational market ) joint within 3 month Screening IA hyaluronic acid ( investigational market ) index knee within 6 month Screening IV IM corticosteroid ( investigational market ) within 3 month Screening Oral corticosteroid ( investigational market ) within 1 month Screening Inhaled , intranasal topical corticosteroid ( investigational market ) within 2 week Screening Any IA investigational drug/biologic within 6 month Screening Prior use FX006 Use acetaminophen , acetaminophen contain product Current use continuous glucose monitoring device Women childbearing potential use effective contraception pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Knee</keyword>
	<keyword>Pain</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Intra-articular</keyword>
	<keyword>Injection</keyword>
</DOC>